A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 223-229

  Kosten, Therese A ^a   Shen, Xiaoyun Y ^a   O'Malley, Patrick W ^a   Kinsey, Berma M ^a   Lykissa, Ernest D ^c   Orson, Frank M ^a,b   Kosten, Thomas R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Immunology Allergy and Rheumatology   (United States)

^c ExperTox   (United States)

Author keywords

Antinociception; Conditioned place preference; Heroin metabolites; Immunotherapy; Opioid dependence

Indexed keywords

DIAMORPHINE; DRUG ANTIBODY; DRUG METABOLITE; KEYHOLE LIMPET HEMOCYANIN 6 SUCCINYLMORPHINE; MORPHINE; MORPHINE CONJUGATE VACCINE; MORPHINE SULFATE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; MALE; NONHUMAN; OPIATE ADDICTION; PLACE PREFERENCE; RAT; TREATMENT RESPONSE; VACCINATION; VACCINE PRODUCTION;

3-GM; 50% INHIBITION OF MAXIMUM BINDING; 6-ACETYL MORPHINE; 6-AM; 6-GM; 6-SM; 6-SUCCINYLMORPHINE; ALUM; ALUMINUM HYDROXIDE GEL; ANTINOCICEPTION; BOVINE SERUM ALBUMIN; BSA; CONDITIONED PLACE PREFERENCE; CPP; EDC; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAS-CHROMATOGRAPHY COUPLED TO MASS SPECTROMETRY; GC-MS; HEROIN METABOLITES; IC50; IMMUNOTHERAPY; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE LIMPET HEMOCYANIN-6-SUCCINYLMORPHINE; KLH; KLH-6-SM; MAXIMAL POSSIBLE EFFECT; MORPHINE-3-GLUCURONIDE; MORPHINE-6-GLUCURONIDE; MPE; N-(3-DIMETHYLAMINOPROPYL)-N′-ETHYLCARBODIIMIDE HYDROCHLORIDE; N-HYDROXYSULFOSUCCINIMIDE; OPIOID DEPENDENCE; SULFO-NHS;

ANALGESICS; ANIMALS; ANTIBODIES; CONDITIONING (PSYCHOLOGY); HEMOCYANIN; HEROIN; MORPHINE; RATS; VACCINES, CONJUGATE;

EID: 84880015973     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.05.012     Document Type: Article

References (34)

1. Akbarzadeh A., Mehraby M., Zarbakhash M., Farzaneh H. Design and synthesis of morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem 1999, 30:139-146.
2. Anton B., Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006, 24:3232-3240.
3. Anton B., Salazar A., Flores A., Matus M., Marin R., Hernandezet J.A. Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin 2009, 5:214-229.
4. Berkowitz B., Spector S. Evidence for active immunity to morphine in mice. Science 1972, 22:1290-1292.
5. Bonese K.F., Wainer B.H., Fitch F.W., Rothberg R.M., Schuster C.R. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974, 252:708-710.
6. Carr G.D., Fibiger H.C., Phillips A.G. Conditioned place preference as a measure of drug reward. The neuropharmacological basis of reward 1989, 264-319. Oxford University Press, New York. J. Liebman, S. Cooper (Eds.).
7. Cicero T.J., Ennis T., Ogden J., Meyer E.R. Gender differences in the reinforcing properties of morphine. Pharmacol Biochem Behav 2000, 65:91-96.
8. deWit H., Bodker B., Amber J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology 1992, 107:352-358.
9. Gross S.J., Grant J.D., Wong S.R., Schuster C.R. Critical antigenic determinants for production of antibody to distinguish morphine from heroin, codeine, and dextromethorphan. Immunochemistry 1974, 11:453-456.
10. Haney M., Gunderson E.W., Jiang H., Collins E.D., Foltin R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010, 67:59-65.
11. Hatsukami D.K., Jorenby D.E., Donzales G., Aigotti R.N., Glover E.D., Oncken C.A., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011, 89:392-399.
12. Hill J.H., Wainer B.H., Fitch F.W., Rothberg R.M. Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6-hemisuccinate bovine serum albumin. J Immunol 1975, 114:1363-1368.
13. Inturrisi C.E., Schultz M., Shin S., Umans J.G., Simons E.J. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 1983, 33:773-776.
14. Kahan M., Srivastava A., Ordean A., Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2001, 57:281-289.
15. Koida M., takahashi M., Muraoka S., Kaneto H. Antibodies to BSA conjugates of morphine derivatives: strict dependency of the immunological specificity on the hapten structure. Jpn J Pharmacol 1974, 24:165-167.
16. Kreek M.J., Borg L., Ducat E., Ray B. Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis 2010, 29:200-216.
17. Ma L.X., Zhou Q., Zheng H.B., Li S.B. Preparation and characterization of anti-morphine vaccine antibody. Chinese Cell Mol Immunol 2006, 22:368-370.
18. Marsch L.A., Bickel W.K., Badger G.J., Rathmell J.P., Swedberg M.D.B., Jonzon B., et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001, 299:1056-1065.
19. Martell B.A., Orson F.M., Poling J., Mitchell E., Rossen R.D., Gardner T., et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009, 66:1116-1123.
20. Maxwell S., Shinderman M.S. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis 2002, 21:1-12.
21. NIH Guide for the care and use of laboratory animals 1996, National Academy Press, Washington D.C.
22. Reid L.D., Hunter G.A., Beaman C.M., Hubbell C.L. Toward understanding ethanol's capacity to be reinforcing: a conditioned place preference following injections of ethanol. Pharmacol Biochem Behav 1985, 22:483-487.
23. Selley D.E., Cao C.C., Sexton T., Schwegel J.A., Martin T.J., Childers S.R. m-Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monacetylmorphine compared to morphine. Biochem Pharmacol 2001, 62:447-455.
24. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clin Pharmacol Ther 2012, 91:60-70.
25. Shen X.Y., Kosten T.A., Lopez A.Y., Kinsey B.M., Kosten T.R., Orson F.M. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend 2013, 129:41-48.
26. Simon E.J., Dole W.P., Hiller J.M. Coupling of a new, active morphine derivative to sepharose for affinity chromatography. Proc Natl Acad Sci 1972, 69:1835-1837.
27. Stotts A.L., Dodrill C.L., Kosten T.R. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009, 10:1727-1740.
28. Stowe G.N., Vendruscolo L.F., Edwards S., Schlosburg J.E., Misra K.K., Schulteis G., et al. A vaccine strategy that induces protective immunity against heroin. J Med Chem 2011, 54:5195-5204.
29. UNODC United Nations Office on Drugs and Crime: World Drug Report, Vol. Sales No. E.10.XI.13 2010, United Nations Publication.
30. VanVunakis H., Wasserman E., Levine L. Specificities of antibodies to morphine. J Pharmacol Exp Ther 1972, 180:514-521.
31. Veilleux J.C., Colvin P.J., Anderson J., York C., Heinz A.J. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010, 30:155-166.
32. Wainer B.H., Fitch F.W., Rothberg R.M., Fried J. Morphine-3-succinyl-bovine serum albumin: an immunogenic hapten-protein conjugate. Science 1972, 176:1143-1145.
33. Wainer B.H., Fitch F.W., Fried J., Rothberg R.M. A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding. Clin Psychol Rev 1973, 30:155-166.
34. Woolverton W.L., Wang Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 2004, 486:251-257.